-
Gentium Submits New Drug Application to FDA
Wednesday, July 6, 2011 - 7:33am | 49Gentium S.p.A. (NASDAQ: GENT) today announced that it has submitted a New Drug Application to the United States Food and Drug Administration for Defibrotide for the treatment of hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem-cell transplantation.
-
Goldman Sachs Downgrades Cepheid To Neutral, $35 PT
Wednesday, July 6, 2011 - 7:15am | 24Goldman Sachs has downgraded Cepheid (NASDAQ: CPHD) from Buy to Neutral and maintains its $35 price target.
-
Oncolytics Biotech Collaborators Present Positive REOLYSIN Clinical Trial Results at the 14th World Conference on Lung Cancer
Wednesday, July 6, 2011 - 7:02am | 82Oncolytics Biotech Inc. (NASDAQ: ONCY) today announced that a presentation covering interim preliminary results from a Phase 2 clinical trial using intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer with Kras or EGFR-...
-
Pharmasset Enters into a Clinical Collaboration Agreement with Tibotec Pharmaceuticals for a Combination Study in Patients Chronically Infected with Hepatitis C
Wednesday, July 6, 2011 - 6:51am | 145Pharmasset, Inc. (NASDAQ: VRUS), announced today that it has entered into a clinical collaboration agreement with Tibotec Pharmaceuticals to evaluate in a Phase 2 study the safety and efficacy of PSI-7977, Pharmasset's investigational nucleotide polymerase inhibitor, in combination with TMC435,...
-
Citi Provides Color on Human Genome Sciences
Wednesday, July 6, 2011 - 6:49am | 198Citi provided color on Human Genome Sciences (NASDAQ: HGSI). In a research report published today, Citi commented on the company's testing of new products. In the report, Citi states, “GSK is developing the drug and HGS is eligible to receive royalty payments. Our physician expert was highly...
-
Amgen and UCB Team Up With NASA on Final Space Shuttle Mission to Conduct Preclinical Test of Sclerostin Antibody on Bone Loss
Tuesday, July 5, 2011 - 4:33pm | 222Amgen (NASDAQ: AMGN) and UCB announced today that they are collaborating with the National Aeronautics and Space Administration Ames Research Center to conduct a preclinical test of a sclerostin antibody in an experiment that will take place aboard space shuttle Atlantis, on the final NASA shuttle...
-
NASDAQ Stocks Hitting 52-Week Lows
Tuesday, July 5, 2011 - 10:31am | 130Syntroleum Corporation (NASDAQ: SYNM) shares fell 2.05% to create a new 52-week low of $1.43. SYNM's trailing-twelve-month profit margin is -275.76%. Smith Micro Software Inc (NASDAQ: SMSI) shares dropped 5.20% to create a new 52-week low of $3.83. SMSI's PEG ratio is -1.46. Novavax Inc (NASDAQ:...
-
Inovio Pharmaceuticals Synthetic DNA Vaccine Protects Against HIV in Non-Human Primates
Tuesday, July 5, 2011 - 9:44am | 278Inovio Pharmaceuticals, Inc. (NYSE: INO) announced today that novel data from a preclinical study of its SynCon™ DNA vaccine against HIV were published in two separate scientific journals. In vaccinated animals, the studies demonstrated Inovio's HIV vaccine's ability to harness the power of the...
-
Market Update
Tuesday, July 5, 2011 - 9:36am | 182Shares of Immucor Inc (NASDAQ: BLUD) surged about 30.2% after the company agreed to be bought by TPG Capital in a deal worth $1.97 billion or $27 per share in cash. The price represents a 30% premium over BLUD's closing share price on July 1. The transaction is likely to close in the second half of...
-
Poniard Pharmaceuticals Announces Intention to Adjourn Annual Meeting of Shareholders to Solicit Additional Proxies for Reverse Stock Split Proposal
Tuesday, July 5, 2011 - 8:32am | 136Poniard Pharmaceuticals, Inc. (NASDAQ: PARD) announced today that it intends to adjourn its annual meeting of shareholders scheduled for Friday, July 8, 2011, until Friday, July 22, 2011, in order to solicit additional proxies to vote in favor of a proposal authorizing the Company's Board of...
-
CytRx Receives FDA Orphan Drug Designation for INNO-206 for the Treatment of Soft Tissue Sarcomas
Tuesday, July 5, 2011 - 8:32am | 84CytRx Corporation (Nasdaq: CYTR), a biotechnology company specializing in oncology, today announced that the Office of Orphan Product Development of the U.S. Food and Drug Administration has granted INNO-206 orphan drug designation for the treatment of patients with soft tissue sarcomas. Soft...
-
Biggest Pre-Market Winners and Losers
Tuesday, July 5, 2011 - 7:42am | 167Winners: Novozymes A/S (PINK: NVZMF) is up over 6%. Apollo Group (NASDAQ: APOL) is up over 5%. Marathon Oil (NYSE: MRO) is up over 4% after completing spinoff of oil refiner. Dendreon (NASDAQ: DNDN) is up over 3.50%. Cablevision Systems (NYSE: CVC) is up nearly 3.50%. Losers: Discover...
-
A Peek Into The Market Before The Trading Starts
Tuesday, July 5, 2011 - 7:36am | 369Pre-open movers US stock futures are higher this morning, as investors are awaiting factory-orders data. Futures on the Dow Jones Industrial Average surged 22 points to 12,536.00 and futures on the S&P 500 stock index rose 0.30 point to 1,335.10. Nasdaq 100 futures gained 8.00 points to 2,363....
-
Oncolytics Biotech Announces Appointment of Dr. George M. Gill as Chief Medical Officer
Tuesday, July 5, 2011 - 7:07am | 44Oncolytics Biotech Inc. (NASDAQ: ONCY) today announced the appointment of George M. Gill, MD as Chief Medical Officer. He has been Senior Vice President of Clinical Safety and Regulatory Affairs and an officer of Oncolytics since 2002.
-
Rodman & Renshaw Provides Color on BioCryst Pharmaceuticals
Tuesday, July 5, 2011 - 7:02am | 199Rodman & Renshaw provided color on BioCryst Pharmaceuticals (NASDAQ: BCRX), following a conversation with Dr. Robert Terkeltaub. In a research report published today, Rodman & Renshaw commented on the rise of prevalence of gout among the elderly population in the United States. In the...